Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
Betsy Goodfellow | November 23, 2023 | News story | Medical Communications | Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis.
The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 or a placebo. NX-13 was well-tolerated in all patients, with no deaths or severe adverse events reported, and only mild to moderate adverse events being observed.
Most patients who received the drug for four weeks showed consistent and rapid clinical improvement in total Mayo score and in symptomatic relief. Endoscopic improvement was observed to correlate closely with symptom improvement.
The drug is now being assessed in the NEXUS trial – a randomised, multi-centre, double-blind, placebo-controlled, multiple dose, statistically powered, phase 2 proof-of-concept study. Results are expected in the fourth quarter of 2024.
Bram Verstockt MD PhD, lead author on the publication, commented: “Despite advances in UC treatments, the need for new and novel therapies such as NX-13 remains highly important for patients. The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging. I am excited about the potential of NX-13 and immunometabolism in breaking the inflammatory cycle in UC, which remains a significant unmet need in effectively treating patients.”
Betsy Goodfellow
Related Content
Cara Therapeutics shares data from part a of notalgia paresthetica trial
Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study …
Tracon shares data from phase 2 trial for glioblastoma treatment
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA …
Eli Lilly shares results for tirzepatide for MASH resolution
Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, …